|
Gene therapy slows progression of fatal neurodegenerative disease in children
May 14, 2008Gene therapy to replace the faulty CLN2 gene, which causes a neurodegenerative disease that is fatal by age 8-12 years, was able to slow significantly the rate of neurologic decline in treated children, according to a paper published online ahead of print in the May 2008 issue (Vol. 19 No. 5) of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc. The paper is available free online at www.liebertpub.com/hum
Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL) is an autosomal recessive genetic disorder that causes degeneration of the central nervous system. It is a form of Batten disease, a group of lysosomal storage disease in which a lipofuscin-like material is not broken down and accumulates in neurons, causing cognitive impairment, visual failure, seizures, and progressive deterioration of motor function.
Ronald Crystal and colleagues from Weill Cornell Medical College (New York, NY), describe a study conducted in 10 children with LINCL who received gene therapy to replace the defective CLN2 gene via administration of human CLN2 carried in an adeno-associated virus (AAV). In the paper entitled "Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis with CNS Administration of a Serotype 2 Adeno-associated virus expressing the CLN2 cDNA," the authors report that over an 18-month period, assessment using a neurologic rating scale demonstrated significant slowing of disease progression in the treated, compared to the untreated children. On the basis of these findings, the authors proposed that additional studies to assess the safety and efficacy of AAV-mediated gene therapy for LINCL be pursued.
Although the treatment was associated with some serious adverse events in some patients, these were not unequivocally attributable to the gene therapy vector.
"This clinical trial is an important step toward the development of treatments for this group of underserved inherited neurodegenerative disorders," says James M. Wilson, MD, PhD, Editor-in-Chief and Head of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, at the University of Pennsylvania School of Medicine, in Philadelphia.
Mary Ann Liebert, Inc./Genetic Engineering News
Although the treatment was associated with some serious adverse events in some patients, these were not unequivocally attributable to the gene therapy vector.
"This clinical trial is an important step toward the development of treatments for this group of underserved inherited neurodegenerative disorders," says James M. Wilson, MD, PhD, Editor-in-Chief and Head of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, at the University of Pennsylvania School of Medicine, in Philadelphia.
Mary Ann Liebert, Inc./Genetic Engineering News
Neurodegenerative Disease News and Current Neurodegenerative Disease Events RSSCan tomatoes carry the cure for Alzheimer's?
The humble tomato could be a suitable carrier for an oral vaccine against Alzheimer's disease, according to HyunSoon Kim from the Korea Research Institute of Bioscience and Biotechnology (KRIBB) in Korea and colleagues from Digital Biotech Inc. and the Department of Biological Science at Wonkwang University. Although their research1, just published online in Springer's journal Biotechnology Letters, is still in the early stages, it is a promising first step towards finding an edible vaccine against the neurodegenerative disease.
Scientists find how neural activity spurs blood flow in the brain
New research from Harvard University neuroscientists has pinpointed exactly how neural activity boosts blood flow to the brain. The finding has important implications for our understanding of common brain imaging techniques such as fMRI, which uses blood flow in the brain as a proxy for neural activity.
Molecular imaging sheds new light on progression of Alzheimer's disease
In the past, physicians were able only to follow the progression of Alzheimer's disease (AD) through careful clinical histories, noting the often subtle changes associated with cognitive decline over a number of years.
RNA Toxicity Contributes to Neurodegenerative Disease, University of Pennsylvania Scientists Say
Expanding on prior research performed at the University of Pennsylvania, Penn biologists have determined that faulty RNA, the blueprint that creates mutated, toxic proteins, contributes to a family of neurodegenerative disorders in humans.
Vaccine triggers immune response, prevents Alzheimer's
A vaccine created by University of Rochester Medical Center scientists prevents the development of Alzheimer's disease-like pathology in mice without causing inflammation or significant side effects.
Researchers find first conclusive evidence of Alzheimer's-like brain tangles in nonhuman primates
Researchers at the Yerkes National Primate Research Center, Emory University, have discovered the first conclusive evidence of Alzheimer's-like neurofibrillary brain tangles in an aged nonhuman primate.
Seeing Alzheimer's amyloids
In an important step toward demystifying the role protein clumps play in the development of neurodegenerative disease, researchers have created a stunning three-dimensional picture of an Alzheimer's peptide aggregate using electron microscopy.
Researchers uncover mechanism of action of antibiotic able to reduce neuronal cell death in brain
Virginia Commonwealth University researchers have discovered how an antibiotic works to modulate the activity of a neurotransmitter that regulates brain functions, which eventually could lead to therapies to treat Alzheimer's disease, Huntington's disease, epilepsy, stroke, dementia and malignant gliomas.
Ground-breaking new insight into the development of Alzheimer's disease
According to estimates there are 85,000 Alzheimer patients in our country and approximately 20,000 new cases every year. This spectacular increase is due to the increasing ageing population. Unfortunately it is still unclear precisely which ageing process forms the basis of this spectacular rise in the occurrence of the disease.
Menstrual blood -- a valuable source of multipotential stem cells?
Researchers seeking new and more abundant sources of stem cells for use in regenerative medicine have identified a potentially unlimited, noncontroversial, easily collectable, and inexpensive source - menstrual blood.
More Neurodegenerative Disease News Articles
| © 2008 BrightSurf.com |